1. Pink Sheet
  2. >>Market Access

Industry Slams UK Plan To ‘Demand A Third’ Of Drug Company Revenue In Q2/Q3 2025

 
• By Neena Brizmohun

The government wants to raise the statutory scheme payment rate for newer branded medicines from 15.5% to 32.2%, after sales data for Q2 and Q3 2024 showed “higher than expected newer medicines sales growth.”

Man gives a British sterling money bag.
The ABPI said that payment rates under the statutory and voluntary schemes were rocketing
Key Takeaways
  • The UK government is proposing to increase the statutory scheme headline payment percentage to 23.8% in 2025, 24.7% in 2026 and 26.4% in 2027.
  • The rate is the amount of revenue that companies are required to hand back to government on their sales of branded medicines to the National Health Service.
  • The proposed payment rate sets a new record for any such medicines sales payment scheme in the UK and shows that the UK medicines market “is fundamentally broken,” says the Association of the British Pharmaceutical Industry.
  • Comments on the proposal can be submitted to the government by 25 April.

Britain’s drug industry association has criticized the UK government’s proposal to raise the statutory scheme payment rate for newer branded medicines from 15.5% to 32.2% of companies' sales to the...

The planned statutory scheme rate of 32.2%, an average of 23.8% over the whole of 2025, “sets a new record for any such medicines sales payment scheme in the UK,”...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Government Payers

More from Geography

US ‘Most Favored Nation’ Pricing Could be Game Changer for Drug Access In Germany

 
• By Francesca Bruce

In this first in a series of articles looking at the potential impact of the MFN drug pricing policy on European pharmaceutical markets, EUCOPE’s Alexander Natz tells the Pink Sheet why the US policy underscores the importance of confidential net pricing.

ICH Targets RWE, Rare Diseases, Biosimilars, ATMPs In New Guideline Push

 
• By Vibha Sharma

The International Council for Harmonisation has identified four new topics that can benefit from global regulatory alignment, with timelines for initiating work to be determined later.

Quotable: Top Experts On Policy Hot Topics

 
• By Anabel Costa-Ferreira

The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.